A clinical trial to study the effects of Tulsi (Holy basil) on immune status of healthy human subjects

Study of antimicrobial propeties and immunomodulatory effects of Tulsi (Ocimum sanctum Linn) extract. Acronym: ImeT

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2009/091/000350

Enrollment

Registered

2009-11-09

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Intervention1: Tulsi extract (Ocimum sanctum Linn.): Tulsi extract 300mg (Capsule) OD for 28 days Control Intervention1: Placebo: Placebo 300 mg capsule OD 28 days

Eligibility

Inclusion criteria

Inclusion criteria: Apparently healthy, volunteers, adult males or females aged between 18 and 60 years of age with no chronic illness. Not on any regular medication for the last one month.

Exclusion criteria

Exclusion criteria: A history of coronary heart disease or stroke, HIV, TB, Diabetes any other chronic disease, pregnant and lactating women

Design outcomes

Primary

Measure	Time frame
Possible percentage change in the Th1 and Th2 cytokinesTimepoint: Pre and Post intervetion	—

Secondary

Measure	Time frame
CD3+CD4+, CD3+CD8+, CD19+ AND CD16+CD56+Timepoint: Pre and Post intervention;Subjective well being questionaire (STAI-Y1& Y-2) Possible change in the clinical biochemical parameters such as Blood glucose (f), Creatinine, Blood Urea, Total cholestrol,HDL,LDL,Triglycerides, SGOP, SGPT,Na/K,Timepoint: Pre and Post intervention	—

Countries

India

Contacts

Public ContactDr. SC Mahapatra

AIIMS, New Delhi

scmahapatra@gmail.com01126593559

Outcome results